Lucemyra (lofexidine)
Indications for Prior Authorization
Lucemyra (lofexidine)
-
For diagnosis of Opioid withdrawal
Indicated for the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Criteria
Lucemyra
Step Therapy
Length of Approval: 12 Month(s)
- Requested drug is being used for a Food and Drug Administration (FDA)-approved indication AND
- Trial and failure (of a minimum 30-day supply), contraindication, or intolerance to clonidine
P & T Revisions
2024-01-03, 2023-01-04, 2022-01-06, 2021-01-06, 2020-01-17
References
- Lucemyra Prescribing Information. USWM, LLC. Louisville, KY. September 2020.
Revision History
- 2024-01-03: Annual review: No updates required.
- 2023-01-04: Annual review: Updated criteria.
- 2022-01-06: Annual review: Updated criteria and background.
- 2021-01-06: Annual review: No updates required.
- 2020-01-17: Annual review: no updates required.